参一胶囊联合FOLFOX4方案治疗晚期大肠癌35例分析

    Ginsenoside Rg3 capsules combined with FOLFOX4 regimen for treatment of advanced colon cancer: a report of 35 cases

    • 摘要: 目的:观察参一胶囊联合FOLFOX4方案化疗治疗晚期大肠癌的疗效、毒副反应、细胞免疫功能的变化。方法:将67例晚期大肠癌患者按照治疗方案不同随机分为两组:A组单纯接受FOLFOX4方案化疗,B组在化疗同时联合应用参一胶囊。结果:A、B两组近期客观疗效(完全缓解+部分缓解)分别为40.6%和45.7%,差异无统计学意义(P>0.05),B组血液学毒性发生率低于A组(P<0.05),在生活质量和免疫功能改善方面两组差异均有统计学意义(P<0.05~P<0.01)。结论:参一胶囊可减轻化疗毒副反应,有利于改善患者生活质量和免疫功能。

       

      Abstract: Objective: To observe the effect,adverse reaction and cytoimmunity function of ginsenoside Rg3 capsules combined with FOLFOX4 regimen in treatment of advanced colon cancer.Methods: Sixty-seven patients were randomly divided into two groups.Group A(32 cases) received FOLFOX4 regimen only,and Group B(35 cases) were treated with ginsenoside Rg3 capsules plus FOLFOX4 regimen.Results: The response rate was 40.6% in group A and 45.7% in group B(P>0.05).A lower response rate of leucopenia occurred in group B compared with that in group A(P<0.05-P<0.01).The difference was significant in the elevation of T lymphocyte subset and life quality between the two groups.Conclusions: Ginsenoside Rg3 capsules can decrease the side effects of chemotherapy and improve the immunity and life quality of the patients with advanced colon cancer.

       

    /

    返回文章
    返回